07/03/2024 - Adaptive Biotechnologies Corporation: Initial Statement of Beneficial Ownership - Form 3

Ownership Submission

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number:3235-0104Expires:January 31, 2005Estimated average burden hours per response...0.5

1. Name and Address of Reporting Person * BOBULSKY SUSAN 2. Date of Event Requiring Statement (Month/Day/Year) 2024-01-25 3. Issuer Name and Ticker or Trading Symbol Adaptive Biotechnologies Corp [ADPT] (Last) (First) (Middle) C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION , 1165 EASTLAKE AVENUE EAST 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below) Chief Commercial Officer, MRD / 5. If Amendment, Date Original Filed(Month/Day/Year) (Street) SEATTLE WA 98109 6. Individual or Join/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security 2. Amount of Securities Beneficially Owned 3. Ownership Form: Direct (D) or Indirect (I) 4. Nature of Indirect Beneficial Ownership

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivate Security	2. Date Exercisable and Expiration Date	3. Title and Amount of Securities Underlying Derivative Security	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)	6. Nature of Indirect Beneficial Ownership
Date Exercisable	Expriation Date	Title	Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address	Relationships
Director	10% Owner	Officer	Other
BOBULSKY SUSAN C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION 1165 EASTLAKE AVENUE EAST SEATTLE, WA98109			Chief Commercial Officer, MRD

Signatures

/s/ Susan Bobulsky by Stacy L. Taylor, Attorney-in-Fact	2024-03-06
**Signature of Reporting Person	Date

Explanation of Responses:

(*)	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
(**)	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	The options are fully exercisable.
(2)	The options will vest with respect to 1/4 of such shares on February 27, 2021, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
(3)	The options will vest with respect to 1/4 of such shares on August 6, 2021, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
(4)	The options will vest with respect to 1/4 of such shares on March 4, 2022, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
(5)	The options will vest with respect to 1/4 of such shares on March 4, 2023, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
(6)	The options will vest with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Attachments

• Original Link
• Permalink

Disclaimer

Adaptive Biotechnologies Corporation published this content on 06 March 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 07 March 2024 00:41:32 UTC.